Growing digital therapeutics Hygieia programs a scalable d-Nav insulin management system that leverages AI to optimize insulin dosing based on dynamic glucose patterns, indicating strong potential for expansion into clinics and digital health networks seeking diabetes management solutions.

Series B traction Recent $22M Series B funding signals investor confidence and a runway for market expansion, making this a timely window for partnerships, co-marketing, and channel collaborations to accelerate adoption of the d-Nav platform.

Leadership momentum New leadership appointments including a VP of Business Development and a CEO in recent years suggest strategic emphasis on business growth, partnerships, and scale, presenting opportunities for enterprise sales and cross-functional collaborations.

Clinical validation Peer-reviewed studies and reported A1c improvements provide credible clinical evidence that can be leveraged in hospital systems, payers, and risk-sharing arrangements to justify adoption and reimbursement considerations.

Mid-market fit With a lean team and revenue in the low millions, Hygieia aligns with mid-market healthcare providers and device distributors seeking innovative, cost-effective diabetes management solutions, creating channel and OEM partnering opportunities.